Financials in USD. Standardized financial statements.
A compact view of how Biostar Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | FY 2007 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $2.38M | $27.13M | $61.42M | $52.73M | $49.32M | $91.97M | $80.22M | $53.32M | $33.91M | $15.89M |
| Revenue Growth? | -91.2% | -55.8% | +16.5% | +6.9% | -46.4% | +14.6% | +50.4% | +57.2% | +113.5% | 0.0% |
| Cost of Revenue? | $1.47M | $16.03M | $31.14M | $27.05M | $19.47M | $27.58M | $20.08M | $14.31M | $14.06M | $5.22M |
| Gross Profit? | $915,174 | $11.10M | $30.28M | $25.68M | $29.85M | $64.39M | $60.13M | $39.00M | $19.85M | $10.66M |
| Gross Margin? | +38.4% | +40.9% | +49.3% | +48.7% | +60.5% | +70.0% | +75.0% | +73.2% | +58.5% | +67.1% |
| Operating Expenses? | $4.48M | $34.86M | $31.59M | $24.61M | $41.99M | $46.23M | $36.52M | $23.90M | $12.09M | $5.82M |
| Operating Income? | -$3.56M | -$23.76M | -$1.31M | $508,221 | -$20.18M | $18.16M | $23.61M | $15.10M | $7.76M | $4.85M |
| EBITDA? | -$1.70M | -$21.19M | $4.78M | $5.81M | -$19.66M | $18.99M | $24.07M | $15.71M | $8.41M | $5.43M |
| Income Before Tax | -$3.04M | -$23.79M | $1.53M | $2.66M | -$21.57M | $18.07M | $23.45M | $14.75M | $7.72M | $4.79M |
| Income Tax Expense | $2.65M | $1.32M | -$3.31M | $1.85M | -$1.58M | $5.89M | $6.07M | $4.25M | $1.03M | $821,436 |
| Net Income? | -$5.70M | -$25.11M | $4.85M | $809,046 | -$20.00M | $12.17M | $17.38M | $10.50M | $6.69M | $3.96M |
| EPS? | $-2.50 | $-11.36 | $2.30 | $0.49 | $-14.63 | $9.17 | $13.86 | $7.14 | $4.83 | $4.20 |
| Diluted EPS? | $-2.50 | $-11.36 | $2.30 | $0.49 | $-14.63 | $9.17 | $13.23 | $6.72 | $4.62 | $3.99 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality